Immunovant, Inc. (IMVT): Price and Financial Metrics

Immunovant, Inc. (IMVT)

Today's Latest Price: $41.74 USD

0.45 (-1.07%)

Updated Jan 25 4:00pm

Add IMVT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

IMVT Stock Price Chart Interactive Chart >

Price chart for IMVT

IMVT Price/Volume Stats

Current price $41.74 52-week high $53.75
Prev. close $42.19 52-week low $8.34
Day low $39.71 Volume 352,000
Day high $42.23 Avg. volume 384,833
50-day MA $47.95 Dividend yield N/A
200-day MA $34.10 Market Cap 4.09B

Immunovant, Inc. (IMVT) Company Bio

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Latest News Stream

Event/Time News Detail
Loading, please wait...

IMVT Latest Social Stream

Loading social stream, please wait...

View Full IMVT Social Stream

Latest IMVT News From Around the Web

Below are the latest news stories about Immunovant Inc that investors may wish to consider to help them evaluate IMVT as an investment opportunity.

Stifel Nicolaus Stick to Their Buy Rating for Immunovant By

Stifel Nicolaus Stick to Their Buy Rating for Immunovant | January 21, 2021

LifeSci Capital Stick to Their Buy Rating for Immunovant By

LifeSci Capital Stick to Their Buy Rating for Immunovant | January 20, 2021

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

* Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed products * Dr. Jain’s broad and diverse clinical experience makes her uniquely well-suited to lead the initiation of multiple Phase 3 programs for IMVT-1401 across different therapeutic areasNEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Rita Jain, M.D. as Chief Medical Officer. Dr. Jain brings over 20 years of drug development and biopharmaceutical leadership experience to Immunovant, including industry-leading experience in both early and lat...

Yahoo | January 12, 2021

LifeSci Capital Stick to Their Buy Rating for Immunovant

LifeSci Capital Stick to Their Buy Rating for Immunovant | January 5, 2021

The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) ALX Oncology Holdings Inc (NASDAQ: ALXO ) (announced an oncology collaboration with Zymeworks Inc (NYSE: ZYME )) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Biodesix Inc (NASDAQ: BDSX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN C4 Therapeutics Inc (NASDAQ: CCCC ) Champions Oncology Inc (NASDAQ: CSBR ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Edwards Lifesciences Corp (NYSE: EW ) Generation Bio Co (NASDAQ: GBIO ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc...

Benzinga | November 18, 2020

Read More 'IMVT' Stories Here

IMVT Price Returns

1-mo N/A
3-mo -0.55%
6-mo 83.80%
1-year 165.86%
3-year N/A
5-year N/A
YTD -9.63%
2020 191.05%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8197 seconds.